Ausbil Investment Management Ltd Sells 11,053 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Ausbil Investment Management Ltd lowered its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 83.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,193 shares of the medical instruments supplier’s stock after selling 11,053 shares during the quarter. Ausbil Investment Management Ltd’s holdings in LeMaitre Vascular were worth $201,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. NBC Securities Inc. increased its holdings in shares of LeMaitre Vascular by 73.2% during the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 183 shares during the period. USA Financial Formulas bought a new position in LeMaitre Vascular during the third quarter valued at about $60,000. GAMMA Investing LLC raised its holdings in LeMaitre Vascular by 34.3% in the 3rd quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock valued at $68,000 after acquiring an additional 188 shares in the last quarter. KBC Group NV raised its holdings in LeMaitre Vascular by 58.4% in the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock valued at $102,000 after acquiring an additional 410 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of LeMaitre Vascular in the 4th quarter worth approximately $158,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Stock Down 3.2 %

NASDAQ:LMAT opened at $96.93 on Friday. The firm has a market cap of $2.18 billion, a PE ratio of 52.97, a price-to-earnings-growth ratio of 2.20 and a beta of 0.96. LeMaitre Vascular, Inc. has a 12 month low of $56.61 and a 12 month high of $109.58. The company’s 50-day moving average price is $97.41 and its two-hundred day moving average price is $92.85.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. During the same period in the prior year, the company earned $0.33 EPS. LeMaitre Vascular’s revenue for the quarter was up 15.6% on a year-over-year basis. On average, research analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

Insider Transactions at LeMaitre Vascular

In other news, Director Bridget A. Ross sold 3,750 shares of the company’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $101.47, for a total transaction of $380,512.50. Following the transaction, the director now directly owns 2,278 shares in the company, valued at approximately $231,148.66. This represents a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 10.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on LMAT shares. Cantor Fitzgerald began coverage on LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price objective on the stock. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Oppenheimer reaffirmed an “outperform” rating and set a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Finally, Barrington Research upped their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $94.57.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.